John M Kirkwood Selected Research

Immunotherapy

5/2024	GZ17-6.02 kills PDX isolates of uveal melanoma.
4/2024	Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma.
4/2024	Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
2/2024	Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
12/2023	Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts.
2/2023	Immunotherapy in Melanoma: Recent Advances and Future Directions.
1/2023	Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional study.
12/2022	Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
1/2022	Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
1/2022	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John M Kirkwood Research Topics

Disease

293	Melanoma (Melanoma, Malignant) 04/2024 - 01/2002
163	Neoplasms (Cancer) 05/2024 - 01/2002
37	Neoplasm Metastasis (Metastasis) 03/2024 - 03/2002
12	Disease Progression 12/2023 - 06/2011
11	Exanthema (Rash) 12/2023 - 06/2011
10	Diarrhea 12/2023 - 06/2009
10	Brain Neoplasms (Brain Tumor) 01/2023 - 06/2004
8	Fatigue 12/2023 - 09/2002
7	Uveal melanoma 05/2024 - 01/2019
7	Renal Cell Carcinoma (Grawitz Tumor) 12/2016 - 09/2002
6	Neutropenia 08/2015 - 10/2006
5	Fever (Fevers) 12/2023 - 07/2009
5	Lymphatic Metastasis 01/2019 - 07/2006
5	Colitis 01/2016 - 01/2012
4	Pruritus (Itching) 12/2023 - 02/2013
4	Nevus (Nevi) 01/2018 - 01/2003
4	Human Influenza (Influenza) 01/2014 - 09/2002
3	Skin Neoplasms (Skin Cancer) 02/2024 - 09/2009
3	Anemia 12/2023 - 07/2003
3	Nausea 12/2023 - 06/2011
3	Inflammation (Inflammations) 01/2021 - 03/2010
3	Hemorrhage 01/2020 - 10/2006
3	Infections 01/2019 - 10/2006
3	Tetanus 08/2013 - 11/2009

Drug/Important Bio-Agent (IBA)

49	InterferonsIBA 10/2023 - 01/2002
33	IpilimumabIBA 12/2023 - 12/2010
32	AntigensIBA 11/2021 - 09/2002
31	Biomarkers (Surrogate Marker)IBA 04/2024 - 04/2007
31	VaccinesIBA 11/2021 - 03/2002
29	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2002
27	Peptides (Polypeptides)IBA 01/2022 - 01/2002
25	pembrolizumabIBA 03/2024 - 01/2015
24	Immune Checkpoint InhibitorsIBA 04/2024 - 09/2010
21	Interleukin-2 (IL2)IBA 02/2023 - 01/2002
19	CytokinesIBA 02/2023 - 03/2002
17	Dacarbazine (DIC)FDA LinkGeneric 12/2023 - 04/2004
14	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2023 - 09/2008
14	dabrafenibIBA 10/2023 - 07/2012
14	EpitopesIBA 01/2018 - 01/2002
13	NivolumabIBA 02/2024 - 01/2015
12	trametinibIBA 10/2023 - 03/2017
11	Monoclonal AntibodiesIBA 02/2023 - 10/2008
11	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 07/2006
11	Cancer VaccinesIBA 12/2020 - 01/2002
10	Interferon alpha-2 (Roferon-A)FDA Link 01/2023 - 03/2002
10	VemurafenibIBA 01/2022 - 06/2011
10	HLA-DR Antigens (HLA-DR)IBA 01/2014 - 01/2002
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023 - 05/2004
9	tremelimumabIBA 01/2023 - 10/2007
9	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 04/2002
8	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2017 - 11/2009
8	Temozolomide (Temodar)FDA LinkGeneric 12/2015 - 01/2003
7	Programmed Cell Death 1 ReceptorIBA 10/2023 - 05/2015
7	LigandsIBA 02/2023 - 09/2004
7	Paclitaxel (Taxol)FDA LinkGeneric 01/2016 - 08/2006
6	EnzymesIBA 11/2021 - 03/2002
6	Phosphotransferases (Kinase)IBA 01/2020 - 03/2007
6	Sorafenib (BAY 43-9006)FDA Link 01/2016 - 06/2009
6	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 06/2009
5	CTLA-4 AntigenIBA 04/2023 - 10/2008
5	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 02/2006
5	ChemokinesIBA 01/2023 - 04/2007
4	cobimetinibIBA 01/2022 - 07/2012
4	Dasatinib (BMS 354825)FDA Link 11/2021 - 01/2014
4	incomplete Freund's adjuvantIBA 01/2021 - 11/2009
4	AntibodiesIBA 01/2021 - 01/2002
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2018 - 04/2007
4	Monophenol Monooxygenase (Tyrosinase)IBA 08/2012 - 09/2004
3	tebentafuspIBA 12/2023 - 01/2021
3	talimogene laherparepvecIBA 01/2023 - 09/2017
3	B7-H1 AntigenIBA 01/2023 - 05/2009
3	Lipase (Acid Lipase)FDA Link 11/2022 - 11/2012
3	Messenger RNA (mRNA)IBA 08/2022 - 05/2012
3	Tyrosine Kinase InhibitorsIBA 11/2021 - 06/2014
3	HLA Antigens (Human Leukocyte Antigens)IBA 11/2021 - 09/2010
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2021 - 11/2006
3	Interferon Type IIBA 01/2019 - 10/2007
3	Protein Subunit VaccinesIBA 09/2017 - 02/2009
3	RNA (Ribonucleic Acid)IBA 01/2017 - 03/2004
3	Interleukin-10 (Interleukin 10)IBA 04/2015 - 08/2010
3	MicroRNAs (MicroRNA)IBA 01/2015 - 09/2009
3	Cisplatin (Platino)FDA LinkGeneric 11/2014 - 06/2004
3	ProMune (CpG 7909)IBA 05/2012 - 10/2008
3	InterleukinsIBA 04/2011 - 04/2007
3	Immunodominant EpitopesIBA 01/2011 - 08/2006
3	Immunoglobulin G (IgG)IBA 03/2010 - 10/2007
3	Interferon-alpha2bIBA 02/2009 - 04/2007
3	Indicators and Reagents (Reagents)IBA 02/2008 - 01/2003
2	parsaclisibIBA 03/2024 - 12/2023
2	itacitinibIBA 03/2024 - 12/2023

Therapy/Procedure

150	Therapeutics 04/2024 - 01/2002
60	Immunotherapy 05/2024 - 03/2002
28	Drug Therapy (Chemotherapy) 01/2021 - 01/2003
11	Neoadjuvant Therapy 03/2024 - 07/2006
7	Radiotherapy 05/2013 - 06/2004
5	Biological Therapy 11/2014 - 03/2002
4	Lymph Node Excision (Lymph Node Dissection) 02/2018 - 07/2006
4	Aftercare (After-Treatment) 01/2016 - 06/2004
3	Chemoprevention 01/2019 - 08/2008
3	Immunomodulation 01/2011 - 12/2007